

ForPatients

by Roche

Geographic Atrophy Age-Related Macular Degeneration

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Trial Status
Terminated

Trial Runs In
19 Countries

Trial Identifier
NCT02745119 2016-000423-13
GX30191

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02745119 2016-000423-13 GX30191
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No
